199 related articles for article (PubMed ID: 23813644)
1. Are ongoing trials on hematologic malignancies still excluding older subjects?
Cherubini A; Pierri F; Gasperini B; Zengarini E; Cerenzia A; Bonifacio E; Falcinelli F; Lattanzio F
Haematologica; 2013 Jul; 98(7):997-1000. PubMed ID: 23813644
[No Abstract] [Full Text] [Related]
2. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
[TBL] [Abstract][Full Text] [Related]
3. [Leukemias in advanced age. Part 2: Myelodysplastic syndrome and chronic leukemia].
Jehn U
Fortschr Med; 1994 May; 112(13):180-4. PubMed ID: 8020858
[TBL] [Abstract][Full Text] [Related]
4. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell transplantation in hematologic malignancy.
Archuleta TD; Devetten MP; Armitage JO
Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
[TBL] [Abstract][Full Text] [Related]
6. Biannual report of the Cochrane Haematological Malignancies Group.
Trelle S; Higgins G; Kober T; Engert A
J Natl Cancer Inst; 2004 Aug; 96(15):E2. PubMed ID: 15292394
[No Abstract] [Full Text] [Related]
7. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron E
Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
[TBL] [Abstract][Full Text] [Related]
8. Real-time quantitation of bcr-abl transcripts in haematological malignancies.
Saffroy R; Lemoine A; Brézillon P; Frénoy N; Delmas B; Goldschmidt E; Souleau B; Nedellec G; Debuire B
Eur J Haematol; 2000 Oct; 65(4):258-66. PubMed ID: 11073166
[TBL] [Abstract][Full Text] [Related]
9. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Mughal TI; Cross NC; Padron E; Tiu RV; Savona M; Malcovati L; Tibes R; Komrokji RS; Kiladjian JJ; Garcia-Manero G; Orazi A; Mesa R; Maciejewski JP; Fenaux P; Itzykson R; Mufti G; Solary E; List AF
Haematologica; 2015 Sep; 100(9):1117-30. PubMed ID: 26341525
[TBL] [Abstract][Full Text] [Related]
10. Speaking a common language in MDS/MPNs.
Steensma DP
Blood; 2015 Mar; 125(12):1849-51. PubMed ID: 25792730
[TBL] [Abstract][Full Text] [Related]
11. Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry.
Leinonen MK; Rantanen M; Pitkäniemi J; Malila N
Acta Oncol; 2016 Jun; 55(6):782-6. PubMed ID: 26767306
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic and myeloproliferative disorders in children.
Hasle H
Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders.
Kelemen K; Saft L; Craig FE; Orazi A; Nakashima M; Wertheim GB; George TI; Horny HP; King RL; Quintanilla-Martinez L; Wang SA; Rimsza LM; Reichard KK
Am J Clin Pathol; 2021 Feb; 155(2):179-210. PubMed ID: 33367563
[TBL] [Abstract][Full Text] [Related]
14. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
[TBL] [Abstract][Full Text] [Related]
15. Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia.
Hudson CA; Burack WR; Bennett JM
Leuk Res; 2018 Oct; 73():12-15. PubMed ID: 30176385
[TBL] [Abstract][Full Text] [Related]
16. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
17. Interferon therapy of hematologic malignancies.
Foon KA
Cancer Treat Res; 1998; 94():1-21. PubMed ID: 9587679
[No Abstract] [Full Text] [Related]
18. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
19. Editorial: Advances in diagnosis of hematological disorders.
Choudhry VP
Indian J Pediatr; 2013 Sep; 80(9):754-5. PubMed ID: 23943572
[No Abstract] [Full Text] [Related]
20. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
